TrialScientific reports2017

Switching to PegIFNα-2b leads to HBsAg loss in patients with low HBsAg levels and HBV DNA suppressed by NAs.

Jing Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.